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Mitochondrial Haplogroup and 
the Risk of Acute Kidney Injury 
Following Cardiac Bypass surgery
Nigel s. Kanagasundaram  1,2, Simon V. Baudouin2,3, Sarah Rowling4, Mahesh prabhu4, 
John H. Dark2,4, Timothy H. J. Goodship1,5, Patrick F. Chinnery6 & Gavin Hudson5
Although mitochondrial dysfunction plays a key role in the pathophysiology of acute kidney injury 
(AKI), the influence of mitochondrial genetic variability in this process remains unclear. We explored 
the association between the risk of post-cardiac bypass AKI and mitochondrial haplotype – inherited 
mitochondrial genomic variations of potentially functional significance. Our single-centre study 
recruited consecutive patients prior to surgery. Exclusions included stage 5 CKD, non-Caucasian 
race and subsequent off-pump surgery. Haplogroup analysis allowed characterisation of the study 
population using the common mutations and by phylogenetic supergroup (WXI and HV). Chi-square 
tests for association allowed the identification of potential predictors of AKI for use in logistic regression 
analysis. AKI occurred in 12.8% of the study population (n = 881; male 69.6%, non-diabetic 78.5%, 
median (interquartile range) age 68.0 (61.0–75.0) years). The haplogroup profile comprised H (42.7%), J 
(12.1%), T (10.9%), U (14.4%) and K (7.6%). Although the regression model was statistically significant 
(χ2 = 95.483, p < 0.0005), neither the phylogenetic supergroups nor any individual haplogroup was a 
significant contributor. We found no significant association between common European haplogroups 
and the risk of post-cardiac bypass AKI. However, given the major role of mitochondrial dysfunction in 
AKI, there is a need to replicate our findings in other cohorts and with other aetiologies of AKI.
Acute kidney injury (AKI) is a common adverse outcome of cardiac surgery and affects around 18% of patients1. 
The incidence of more severe AKI, requiring renal support, has been reported at 1–2% across various series2–5 and 
is associated with mortality rates of at least 45%2,4,5.
The pathogenesis of the AKI occurring after cardio-pulmonary bypass may include ischaemia-reperfusion 
injury, inflammation induced in the extracorporeal blood circuit, haemolysis, embolization and 
medication-related injury1. Disruption of cellular energetics appears to be a common pathway for many of these 
factors, as it is in all forms of ischaemic AKI6, with mitochondria playing a pivotal role in this process7. Subtle 
differences in mitochondrial function may, therefore, affect susceptibility to AKI through their impact on cellular 
energy production, free radical generation and metabolic uncoupling.
With this in mind, inherited variation in the mitochondrial genome has not only allowed human populations 
to be categorized into different mitochondrial haplogroups, but may also be of functional significance8; associ-
ations have been found, for instance, between mitochondrial haplotype and Alzheimer’s disease9, Parkinson’s 
disease10 and ischaemic stroke11, and with physiological functions such as sperm motility12. Work undertaken 
within our group has also shown that haplogroup H – the commonest haplotype in European populations12 - was 
associated with improved survival after sepsis in comparison to non-haplogroup H subjects13. This observation 
has physiological credibility as subjects with this haplotype have higher respiratory chain activity12 and so may be 
less prone to the risks of the tissue dysoxia that occurs in sepsis14.
A relationship between mitochondrial genetic variability, mitochondrial function and susceptibility to AKI is, 
therefore, biologically plausible. Our study tested the hypothesis that the development of post-cardiopulmonary 
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bypass AKI was associated with mitochondrial haplogroup. We chose this particular model of AKI because of the 
easy identifiability and relative homogeneity of the renal insult.
Results
AKI, as defined by KDIGO (Kidney Disease Improving Global Outcomes) criteria15, occurred in 12.8% (113) of 
the 881 patients retained for final analysis. Demographics and baseline clinical details are shown in Table 1 with 
a breakdown of their mitochondrial haplogroup profile in Table 2 and clinical outcomes in Table 3. A total of 
990 patients had been recruited between 3rd March 2007 and 28th August 2009 with 41 excluded after failing to 
proceed to surgery (7 died before surgery, in 32 surgery was no longer needed, 2 were withdrawn due to the long 
gap between recruitment and surgery), 49 excluded after proceeding to off-pump surgery and with 19 excluded 
due to failed mitochondrial haplotyping.
A Chi-square test for homogeneity compared the haplogroup distributions of the study and published control 
populations16 for haplogroups H, U, K, J, T and ‘other’ – the latter comprising those with either low numbers or 
lack of data in the control population. A significant difference was found (χ2 = 11.845, p = 0.037) although, on 
post hoc analysis using the z test of two proportions with a Bonferroni correction, this seemed to be due to differ-
ences in the proportions of haplogroup K (study vs control, 7.6 vs 11.7%) and those in the ‘other’ category (12.3 
vs 5%). The frequencies of haplogroup H were comparable (42.7 vs 41.3%).
Chi-square tests for association conducted between KDIGO AKI and the categorical variables shown in 
Table 4 allowed the identification of potential predictor variables for use in logistic regression analysis (Table 5). 
These were chosen on the basis of significance (e.g. age, estimated glomerular filtration rate (eGFR) and bypass 
time categories) or near-significance (e.g. Body Mass Index (BMI) > 30) in the Chi-square analyses or Fisher’s 
Exact test. The non-binary categorisation of surgery type was chosen over the dichotomous alternative due to the 
greater clinical credibility of the association.
The logistic regression model (Table 5) was statistically significant (χ2 = 95.483, p < 0.0005), explained 19.2% 
of the variance in KDIGO AKI (Nagelkerke R2) and correctly classified 87.7% of cases. As shown in Table 5, six 
of the ten predictor variables were statistically significant: age, eGFR, the presence of insulin-treated diabetes, 
bypass time, balloon pump use and ‘other’ cardiac bypass surgeries (non-coronary artery bypass graft (CABG), 
non-valve procedures although numbers were small and 95% confidence intervals were wide). Neither the phy-
logenetic supergroups, WXI and HV, nor any individual haplogroup was a significant predictor of KDIGO AKI 
in this model.
Supplementary Chi-square tests for association showed no significant associations between higher stages of 
AKI and individual haplogroups or the phylogenetic groupings, WXI or HV, although numbers of cases were 
small (as shown in Table 3).
Chi-square tests for association undertaken between each of the 6 predictor variables identified above and 
haplogroup failed to reveal any significant association although at least 3 breaches of cell frequency assumptions 
were evident in each test.
In view of the failure of cell frequency assumptions in the Chi-square tests for association, noted above, sup-
plementary analyses were undertaken. Firstly, haplogroup:non-haplogroup variables were created for the com-
mon mutations within the dataset (e.g. H:non-H, etc.) and for phylogenetic supergroups, which also incorporated 
less common mutations (e.g. WXI:non-WXI) – an approach in keeping with our previous published work13. 
Each pairing was then utilised in Chi-square tests for association against KDIGO AKI. As shown in Table 4, 
none were significant but all met cell frequency assumptions. The WXI:non-WXI pairing was then substituted 
for the multinomial haplogroup variable used in our initial logistic regression model which remained statisti-
cally significant (χ2 = 92.695, p < 0.0005), now explained 18.7% of the variance in KDIGO AKI (Nagelkerke 
R2) and correctly classified 87.9% of cases. Regression analyses were repeated, sequentially, substituting each 
haplogroup:non-haplogroup pairing into the model. No pairing was a significant predictor of KDIGO AKI when 
introduced into this model.
Chi-square tests for association undertaken between each of the 6 predictor variables identified above and 
each of the 9 haplogroup:non-haplogroup pairings revealed significant associations between T:non-T and 
eGFR (χ2 = 8.425 (p = 0.015; Cramer’s V < 0.1)), and between HV:non-HV and both bypass time (7.783 (0.020; 
Cramer’s V < 0.1)) and balloon pump use (4.365 (0.037; Phi −0.07)) although the strength of these associations 
was weak. In view of the multiple hypotheses under test (n = 54), we applied a Bonferroni correction at a sig-
nificance level of α (0.05)/κ (54) and the Benjamini-Hochberg technique17, neither of which found any of these 
associations to remain significant.
Because of a biologically plausible association between haplogroup and the risk of chronic kidney disease 
(CKD), additional logistic regression analysis allowed further observations on T:non-T and eGFR. To facilitate 
this, eGFR was re-categorised as a binomial variable. This was undertaken at two, separate thresholds, chosen to 
map to the limits of the original multinomial function (Table 1): (1) eGFR < 60 vs ≥ 60, and (2) eGFR < 75 vs ≥ 75 
(‘eGFR 75’). The association between T:non-T and eGFR 75 was significant (χ2 8.120, p = 0.004; Phi 0.096). 
Logistic regression analysis, employing eGFR 75 as the dependent variable, identified the following significant 
predictor variables: the T:non-T pairing, age, gender and New York Heart Association (NYHA) class. The model 
was statistically significant, χ2 = 96.342, p < 0.0005, with non-T haplogroup observed as conferring a 1.86 times 
higher odds of a baseline eGFR < 75 (95% CI 1.162–2.973, p = 0.010).
Discussion
Human mitochondrial DNA (mtDNA) encodes 13 protein components of the mitochondrial respiratory chain18. 
Its matrilineal inheritance has led to the accumulation of specific single nucleotide polymorphisms (SNPs) which 
have allowed the mitochondrial genome to be characterized according to different mitochondrial haplogroups19. 
These haplotypes may well be of functional significance9–13 although an association between mitochondrial 
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haplogroup and susceptibility to AKI has yet, to our knowledge, to be described. Nevertheless, it is clear that 
mitochondria play a critical role in both tissue injury and repair in AKI7.
Structural abnormalities such as swelling of individual mitochondria, depletion in total numbers and disrup-
tion of cristal architecture have been noted from the early stages of disease, particularly in the proximal tubule, 
and appear to accompany a marked reduction in respiratory chain activity7. As well as deficits in adenosine 
triphosphate production, mitochondrial disruption leads to the accumulation and release of molecules that can 
propagate inflammation, cell injury and apoptosis; these include non-esterified free fatty acids, reactive oxygen 
species, cytochrome c and mtDNA, itself7. Conversely, their importance in recovery from AKI is evidenced by 
Variable N
Median (25th–75th 
percentiles) Range
eGFR (ml/min/1.73 m2) 881
66.0 (56.0–76.0) 23–125
  <60 290 (32.9%)
  ≥60 < 75 342 (38.8%)
  ≥75 249 (28.3%)
BMI (kg/m2) 881
29.0 (26.2–32.1) 16–45
  <20 10 (1.1%)
  20–25 133 (15.1%)
  >25 </=30 373 (42.3%)
  >30 365 (41.4%)
Total bypass time (min) 881
78.0 (62.0–97.0) 5–406
  ≤60 197 (22.4%)
  >60 ≤ 100 489 (55.5%)
  >100 195 (22.1%)
Number previous heart surgeries 881
0.0 (0- 0) 0–6
  ≥1 37 (4.2%)
Age (years) 881
68.0 (61.0–75.0) 20–89
  ≤60 212 (24.1%)
  >60 < 75 444 (50.4%)
  ≥75 225 (25.5%)
Male gender 613 (69.6%)
Emergency surgery 51 (5.8%)
NYHA class 4 (vs. 1–3) 74 (8.4%)
Hypertensive 575 (65.3%)
Extra-cardiac arteriopathy present 107 (12.1%)
COPDa present 77 (8.7%)
Surgery type
  CABG alone 431 (48.9%)
  Valve alone 287 (32.6%)
  CABG + valve 152 (17.3%)
  Other alone 11 (1.2%)
Interval from MIb to surgery
  No MIb or MI >30 days prior 848 (96.3%)
  MI 1–30 days prior 33 (3.7%)
Cerebrovascular disease present 102 (11.6%)
Left ventricular ejection fraction (%)
  ≥30 836 (94.9%)
  <30 44 (5.0%)
  Not measured 1 (0.1%)
Diabetes management
  Not diabetic 692 (78.5%)
  Diet 33 (3.7%)
  Oral therapy 128 (14.5%)
  Insulin 28 (3.2%)
Intra-aortic balloon pump (IABP) used 15 (1.7%)
Table 1. Demographics and baseline clinical details of study population (n = 881). Median, 25th and 75th 
percentiles and range are shown for continuous variables* and frequencies for categorical variables. *Of the 
continuous variables, only eGFR was normally distributed (Kolmogorov-Smirnov and Shapiro-Wilk test p 
values > 0.05). aCOPD = chronic obstructive pulmonary disease. bMI = myocardial infarction.
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both increases in mitochondrial biogenesis and the negative impact of reduced mitophagy on renal recovery7. 
Therapeutic manipulation of both injury and recovery processes is now being explored and is discussed in more 
detail in reference7. Interestingly, mitochondrial dysfunction may be important in increasing even the suscepti-
bility to AKI with experimental in vitro and in vivo work describing the ‘priming’ of mitochondria to apoptosis in 
hyperglycaemic environments20.
Beyond AKI, both inherited and acquired mitochondrial abnormalities have been described in a range of 
other renal diseases. These often occur as part of multi-system disorder in children and young adults and are 
frequently clinically silent7. Disorders of tubular function predominate, as might be expected given the high local 
energy demands, but mitochondrial dysfunction is also evident in different cystic and glomerular diseases (see 
references in7).
A number of SNPs in the mitochondrial and nuclear genomes affecting mitochondrial function have also 
been associated with more prevalent renal diseases such as type 121 and type 2 diabetic nephropathy22, with 
reduced kidney survival in CKD23 and as predictors of chronic dialysis24. The common, acquired mtDNA4977 
deletion mutation was found to be associated with improved survival in a patient cohort from the HEMO study 
and, although the explanation for this preliminary observation was not clear, there was a trend for these patients 
to have higher mtDNA copy number25. The potential importance of epigenetic factors, has been illustrated by 
an association between type 1 diabetic kidney disease and the DNA methylation of nuclear genes influencing 
mitochondrial function26.
Beyond these genetic factors, mitochondrial dysfunction appears to increase with worsening CKD (see refer-
ences in27) and seems to have a central role in the development of the oxidative stress associated with deteriorat-
ing renal function (see references in28).
To our knowledge, the present study is the first examination of the hypothesis that mitochondrial haplogroup 
influences the risk of developing AKI. The supposition carries biological plausibility given the pivotal role of 
mitochondria in pathogenesis and because subtle differences of function across haplogroups may confer differing 
levels of risk8. We found no influence on the risk of post-cardiac bypass AKI or, in supplementary analysis, on the 
severity of AKI. Our negative findings should be viewed in the context that this was a single-centre study exam-
ining a specific aetiology of AKI.
We also note that, although the main logistical regression model was sufficiently powered for the number of 
potential predictors (Table 5) and AKI incidence (see ‘Statistical analysis’, below), a more subtle effect of hap-
logroup may have been detected in a larger cohort. This should be placed in the context of ours being one of the 
larger cohorts with this phenotype, though.
Our primary analysis utilised the ‘haplogroup’ variable, comprising the different haplogroups and phyloge-
netic supergroups as described under ‘Statistical analysis’, below, and elsewhere29. This multinomial categorisation 
did lead to a failure of cell frequency assumptions in the Chi-square tests for association although this was entirely 
due to inclusion of the single case with ‘R’ haplotyping. Our supplementary analysis, substituting the ‘haplogroup’ 
variable with ‘haplogroup:non-haplogroup’ was conducted with the aim of increasing the denominator (by cre-
ating the ‘non-haplogroup’ category) – a technique used, extensively, including in previous published work from 
our group13. However, this approach assumes an independence between categories that may not be correct as the 
‘non-haplogroup’ category may contain states that have evolutionary proximity to the ‘haplogroup’ state of the 
Mitochondrial haplogroup N
HV 411 (46.7%)
J 107 (12.1%)
T 96 (10.9%)
U 127 (14.4%)
K 67 (7.6%)
R 1 (0.1%)
WXI 72 (8.2%)
Table 2. Mitochondrial haplogroup breakdown of study population (n = 881).
Outcome measure N Mean (SD) Range
KDIGO AKI within 1st 7 days 113 (12.8%)
Renal support within 1st 7 days 25 (2.8%)
Maximum AKI stage
  1 85
  2 20
  3 (Cr criteria only) 8
Hospital mortality 21 (2.4%)
Hospital length of stay (days) 881 10 (5.6) 1–36
Table 3. Outcome measures of study population (n = 881).
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pairing (e.g. ‘non-J’ includes ‘T’, with both ‘J’ and ‘T’ classifiable in the same phylogenetic supergroup, ‘JT’; simi-
larly ‘non-U’ including ‘K’ and ‘non-T’ including ‘J’).
We believe, however, that the approach in this supplementary analysis is justified as a means of further explor-
ing potential associations of interest and note, also, that the multinomial categorisation used for the primary 
‘haplogroup’ variable (HV, J, T, U, K, R, WXI) does not fully resolve the issue of association between different 
states (‘J’ and ‘T’, ‘U’ and ‘K’, etc.).
Given the major role of mitochondrial dysfunction in AKI, our findings require replication in other patient 
groups, including in other types of AKI, and should extend to other abnormalities of mitochondrial and related 
nuclear genetics beyond, simply, haplotype.
Our finding of an association between mitochondrial haplogroup T (versus ‘non-T’) and CKD was unex-
pected and could only be regarded as anecdotal in the context of multiple hypothesis testing. In contrast to AKI, 
however, inherited differences in the mitochondrial genome have, indeed, been associated with CKD.
For instance, haplogroup D was found to be a risk marker for end-stage renal disease in young, Han Chinese 
subjects30. Further, mtDNA haplogroups J and V have been associated with reduced susceptibility to chronic 
renal allograft dysfunction in comparison to haplogroup H31 which has also been associated with a higher risk of 
the development of post-renal transplant diabetes32. Finally, a gene-environment interaction study suggested an 
association between the longevity-associated mt5178A genotype, regular alcohol consumption and better renal 
function in non-diabetic Japanese men33.
Variable (dichotomous ‘yes’ vs. ‘no’, unless otherwise stated)
Pearson Chi-
square (χ2) P value
Strength of 
association (Phi or 
Cramer’s V **) P value
Haplogroup* (HV, J, T, U, K, R, WXI) 4.523 0.606
Gender 1.949 0.163
Age (≤60 years, >60 < 75, ≥75) 18.736 <0.0005 0.146 <0.0005
Urgency (elective, emergency) 0.442 0.506
eGFR category (<60 ml/min/1.73 m2, ≥60 < 75, ≥75) 40.819 <0.0005 0.215 <0.0005
New York Heart Association (NYHA) class (NYHA 1–3, NYHA 4) 0.294 0.588
BMI* (<20 kg/m2, 20–25, >25–30, >30) 6.082 0.108
BMI > 30 3.529 0.06
BMI > 25 0.528 0.468
Diabetic status 2.752 0.097
Diabetes management* (not diabetic, diet, oral therapy, insulin) 18.149 <0.0005 0.144 <0.0005
Diabetes management*a (not diabetic or non-insulin-treated, insulin-treated) 18.107 <0.0005 0.143 <0.0005
Hypertension 1.748 0.186
Extra-cardiac arteriopathy 1.739 0.187
COPD 0.574 0.449
Surgery type* (CABG alone, Valve alone, CABG + valve, other surgery alone) 13.543 0.004 0.124 0.004
Surgery type (CABG + valve, single procedure) 4.004 0.045 0.067 0.045
Total bypass time (≤60 mins, >60 ≤ 100, >100) 24.84 <0.0005 0.168 <0.0005
Interval between surgery and MI*b (No MI or MI > 30 days pre-surgery, MI 
within 30 days pre-surgery) 0.015 0.902
Cerebrovascular disease 1.522 0.217
Left ventricular ejection fraction* (≥30%, <30%, not measured) 6.271 0.043 0.084 0.043
Left ventricular ejection fraction (≥30%, <30%) n.b. 1 missing 6.118 0.013 0.083 0.013
Number previous heart surgeries*c (0, ≥1) 4.567 0.033 0.072 0.033
IABP use* (none, pre-operative, intra-operative, post-operative, intra- & 
post-operative) 25.971 <0.0005 0.172 <0.0005
Any IABP use*a 22.393 <0.0005 0.159 <0.0005
H: non-H 0.319 0.572
J: non-J 0.007 0.932
T: non-T 0.56 0.454
U: non-U 0.137 0.711
K: non-K 0.972 0.324
HV: non-HV 0.067 0.795
JT: non-JT 0.238 0.626
UK: non-UK 0.891 0.345
WXI: non-WXI 3.071 0.08
Table 4. Chi-square test for association between KDIGO AKI and the categorical variables, indicated. *Failed 
assumption that all expected cell counts > 5. **See text for explanation. aFisher’s exact test significant at 
p = <0.0005 (2-sided). bFisher’s exact test non-significant. cFisher’s exact test significant at p = 0.043 (2-sided).
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In conclusion, the present study has found no significant association between common European haplogroups 
and the risk of AKI after cardiac bypass surgery. Our observations require replication in other patient cohorts and 
with different aetiologies of AKI.
Methods
Ethical approval for the study protocol and procedures was received from the Northumberland Local Research 
Ethics Committee (ref: 07/Q0902/30) in accordance with their ethical standards and with the Helsinki 
Declaration of 1975, as revised in 2000.
Consecutive patients were screened for inclusion from the institution’s adult cardiac surgery pre-assessment 
clinic and in-patient wards prior to elective or emergency cardiac bypass surgery. Exclusion criteria comprised: 
age <18 years, pre-existing chronic dialysis or renal transplant, stage 5 CKD (eGFR < 15 mL/min/1.73 m2), 
pre-existing AKI (defined by contemporary consensus criteria34), patients undergoing cardiac or lung transplan-
tation, participation in other studies and non-Caucasian race. After signed, written informed consent, a 10 mL 
EDTA blood sample was collected from each recruited patient. Genomic DNA was extracted (“Nucleon® Total 
Genomic DNA Extraction Kit:” product 44100, Tepnel Life Sciences PLC) and mitochondrial DNA haplotype 
analysis performed using polymerase chain reaction and restriction fragment polymorphism analysis as previ-
ously described35,36.
Data extracted from the clinical record included demographics, pre-operative co-morbidity, surgery type, the 
presence of recognised risk factors for post-cardiac bypass AKI2–5,37–39 and outcome measures (the need for renal 
replacement therapy (RRT) within the 1st 7 post-operative days, hospital length of stay, and in-hospital mortality). 
Post-bypass AKI was determined using the baseline of the pre-operative serum creatinine (SCr) from the day 
prior to surgery or sooner or, if unavailable, the pre-assessment clinic SCr. KDIGO (Kidney Disease Improving 
Global Outcomes) criteria15 were utilised in our analyses to diagnose AKI and stage its severity over the 7 days 
Potential predictor 
variable Category* n B SE Wald df p
Odds 
Ratio 
(OR)
95% C.I. for OR
Lower Upper
Surgery type
CABG alone 431 6.775 3 0.079
Valve alone 287 0.173 0.267 0.423 1 0.516 1.189 0.705 2.005
CABG + valve 152 −0.045 0.328 0.019 1 0.891 0.956 0.503 1.818
Other alone 11 1.811 0.729 6.179 1 0.013 6.119 1.467 25.524
Age (years)
≤60 212 10.674 2 0.005
>60 < 75 444 0.266 0.332 0.640 1 0.424 1.304 0.680 2.501
≥75 225 0.965 0.358 7.260 1 0.007 2.626 1.301 5.300
Ejection fraction (%)
≥30 836 2.788 2 0.248
<30 44 0.700 0.419 2.788 1 0.095 2.014 0.885 4.582
Not measured 1
Total bypass time category 
(mins)
≤60 197 7.591 2 0.022
>60 ≤ 100 489 0.375 0.324 1.336 1 0.248 1.455 0.770 2.747
>100 195 0.956 0.369 6.724 1 0.010 2.603 1.263 5.363
eGFR (ml/min/1.73 m2)
≥75 249 16.739 2 <0.0005
≥60 < 75 342 0.881 0.370 5.660 1 0.017 2.412 1.168 4.984
<60 290 1.445 0.367 15.507 1 <0.0005 4.242 2.066 8.707
Intra-aortic balloon pump 
use
No 866
Yes 15 1.203 0.608 3.917 1 0.048 3.329 1.012 10.953
BMI > 30 kg/m2
No 516
Yes 365 0.394 0.227 3.020 1 0.082 1.483 0.951 2.313
Insulin-treated diabetes
No 853
Yes 28 1.433 0.465 9.499 1 0.002 4.190 1.685 10.419
Number of previous heart 
operations
0 844
≥1 37 0.013 0.469 0.001 1 0.977 1.013 0.404 2.542
Haplogroup**
HV 411 4.899 6 0.557
WXI 72 0.442 0.357 1.533 1 0.216 1.555 0.773 3.129
J 107 −0.111 0.352 0.100 1 0.752 0.895 0.449 1.782
T 96 −0.040 0.387 0.011 1 0.918 0.961 0.450 2.052
U 127 −0.222 0.339 0.431 1 0.512 0.801 0.412 1.556
K 67 −0.718 0.494 2.111 1 0.146 0.488 0.185 1.285
Constant −4.156 0.493 71.137 1 <0.0005 0.016
Table 5. Logistic regression predicting likelihood of KDIGO AKI. Forty-two studentized residuals with 
values > 2.5 standard deviations (range 2.582–6.079) were all retained. *The first category for each potential 
predictor variable represents the reference category (e.g. “CABG alone” for “Surgery type”). **The study cohort 
also included a single case with haplogroup ‘R’ which did not contribute, significantly, to the model.
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post-surgery. Patients listed for cardiac bypass surgery but subsequently undergoing an off-pump procedure were 
excluded from further analysis because of the possible impact on AKI risk1.
SCr was measured using the Jaffé method on an Olympus AU Analyser (Beckman Coulter (UK) Ltd, High 
Wycombe). In order to determine baseline eGFR, the corresponding SCr was adjusted to harmonise with gold 
standard methodology (Isotope Dilution Mass Spectrometry) using the following correction factor, provided by 
the UK-accredited Wales External Quality Assessment Scheme40 in 2006:
− × .(SCr 11) 1 04
Baseline eGFR was then calculated using the revised four-variable MDRD 175 formula for SI units41.
statistical analysis. An independent, multinomial variable, ‘haplogroup’ was created comprising the fol-
lowing categories: J, T, U, K, WXI, R and HV, with the latter used as reference.
The primary, dichotomous dependent variable was post-operative AKI (‘KDIGO AKI’) defined solely by SCr 
criteria15, namely: a rise from baseline of ≥26.5 μmol/L within 48 hours or ≥1.5 fold within 7 days.
A Chi-square test for homogeneity42 compared the haplogroup distributions of the study population and a 
previously described local control population16.
Chi-square tests for association43 were then undertaken between KDIGO AKI and each potential predictor 
variable, including the multinomial haplogroup variable. Continuous variables (e.g. age, eGFR) were converted 
to categorical variables for these analyses. Tests were conducted under the assumption that expected cell frequen-
cies were >5 but where this failed, Fisher’s Exact test was undertaken if the tested variable was dichotomous. The 
strength of any significant association was tested using the Phi statistic for dichotomous variables and Cramer’s V, 
otherwise, with both measures interpreted in the same manner as a correlation (i.e. ranging from −1 to +1 and 
from 0 to +1, respectively). Sensitivity analyses, involving re-categorisation of other variables with potentially 
significant associations, allowed identification of additional potential predictors for use in the regression analysis.
Supplementary Chi-square tests for association were performed to evaluate the association of the multinomial 
haplogroup variable with stage 2 and/or stage 3 AKI.
Binomial logistic regression analysis was then performed44 using KDIGO AKI as the dependent variable and, 
as independent variables, the multinomial haplogroup variable and any other independent variables, found to be 
significant in the Chi-square tests for association, described above.
The impact of haplogroup on any other significant predictors identified from the regression model was then 
explored with further Chi-square tests for association (predictor variable vs haplogroup) and binomial logistic 
regression (if the association was significant and clinically credible).
Supplementary analyses were then performed.
Firstly, haplogroup:non-haplogroup variables were created for the common mutations within the dataset 
(e.g. H:non-H, etc.) and for phylogenetic supergroups, which also incorporated less common mutations (e.g. 
WXI:non-WXI). Chi-square tests for association43 were then undertaken between KDIGO AKI and each hap-
logroup:non-haplogroup pairing. Each binomial pairing was then, sequentially, substituted for the multinomial 
‘haplogroup’ variable used in the primary logistic regression model for prediction of KDIGO AKI. Finally, the 
impact of each haplogroup:non-haplogroup pairing on other, significant predictors of KDIGO AKI, identified 
from this regression model was then explored with further Chi-square tests for association (predictor variable 
vs haplogroup:non-haplogroup pairing) and binomial logistic regression (if the association was significant and 
clinically credible).
Following the recommendation that there should be at least 10 events per variable studied45, for a 10 variable 
model, 100 events would have to occur in the study population; thus, for the reported AKI incidence of 18%1, 
target recruitment would be 556 whilst lower incidences of 15, 12.5 and 10% would increase target recruitment to 
667, 800 and 1000 patients, respectively.
Analyses were performed using the SPSS statistics package (version 22, IBM Corporation) with p < 0.05 being 
regarded as statistically significant. Where percentages are reported (e.g. Tables 1–3), these are rounded to one 
decimal place.
Data Availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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